TRIAL DETAIL

Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Drug:
Trial Name:
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
NCT#:
Conditions:
Gastrointestinal Stromal Tumors; Soft Tissue Sarcomas
Status:
Completed
Phase:
1
Start Date 12/01/2005
Age of Trial (yrs) 16
Treatment Phase:
Gleevec-resistant
Drug Category:
HSP90 inhibitor
Strategy:
Destroy KIT
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
IPI-504-02
Sponsor:
Infinity Pharmaceuticals
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
IV Intravenous
Trial Notes:
IPI-504 is a novel, water-soluble analog of 17-AAG and a potent inhibitor of Hsp90. Hsp90's role in the cell is to control the proper folding, function, and viability of various "client" proteins. Many of these client proteins (such as AKT, Her-2, Bcr-Abl, PDGFR-α, and c-Kit) are oncoproteins or important cell signaling proteins.
In patients with GIST, mutations in the tyrosine kinase receptor Kit play a critical role in the pathogenesis of this disease. Inhibition of Kit signaling with the tyrosine kinase inhibitor Imatinib (IM) is a very effective treatment for GIST patients. However, new mutations arise in Kit conferring resistance to IM treatment which results in disease progression. Kit is a client protein of Hsp90 and is sensitive to IPI-504.
In Soft Tissue Sarcomas, there may be genetic abnormalities that lead to the expression of certain proteins that drive the growth of cancer. These cancer-driving proteins may be stimulated by HSP90. This provides a scientific rationale for Phase 1 clinical testing of IPI-504 in patients with advanced GIST and STS who have failed prior therapies.

Trial Links

 

Trial Results

 
 
 
 

Drug Information

Infinity halts the phase III RING trial in GIST
 
LRG story - IPI-504 completes phase I
 
LRG story - Infinity launches trial of IPI-504 for GIST
 
LRG story - Resistant GIST may fall to new inhibitor
 
LRG story - IPI-504 enters phase III
 
Infinity website - pipeline, IPI-504
 

Trial Sites

Name
Address
City
State
Zip
Country
450 Brookline Ave
Boston
MA
02215-5450
USA
1500 East Medical Center Dr
Ann Arbor
MI
48109
USA
2020 Santa Monica Boulevard Suite 600
Santa Monica
CA
90404
USA
9023 E. Desert Cove Ave.
Scottsdale
AZ
85260
USA
600 University Ave.
Toronto
ON
M5G 1X5
Canada